SCYNEXIS, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
SCYNEXIS, Inc. (SCYX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $317.15 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $40.49, a 54.04% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $88.09, a 1023.60% increase year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $7.84, a 6.67% increase year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $7.35, a 1.21% decline year-over-year.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $30.54, a 15.00% decline from fiscal 2024.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $35.93, a 251.91% increase from fiscal 2023.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $10.21, a 33.99% increase from fiscal 2022.
- SCYNEXIS, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $7.62, a 4.15% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $317.15 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $40.49 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $30.54 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $52.49 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $87.61 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $88.09 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $35.93 10-K · filed 2025-03-12 | |||
| 2024-09-30 | $36.35 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $36.36 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $7.84 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $10.21 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $13.67 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $14.59 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $7.35 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | $7.62 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $7.42 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | $8.15 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $7.44 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $7.95 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $6.68 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $6.72 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $8.48 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $23.50 10-K · filed 2021-03-29 | |||
| 2020-09-30 | $26.46 10-Q · filed 2020-11-06 | |||
| 2020-06-30 | $20.66 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $1.80 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $7.96 10-K · filed 2020-03-11 | |||
| 2019-09-30 | $7.96 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | $6.80 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $9.35 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $5.81 10-K · filed 2019-03-14 | |||
| 2018-09-30 | $6.66 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $7.63 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $4.53 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $9.64 10-K · filed 2019-03-14 | |||
| 2017-09-30 | $9.64 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $9.64 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $9.64 10-Q · filed 2017-05-08 | |||
| 2016-12-31 | $7.47 10-K · filed 2018-03-13 | |||
| 2015-12-31 | $9.05 10-K · filed 2017-03-13 | |||
| 2014-12-31 | $9.57 10-K · filed 2016-03-07 | |||
| 2013-12-31 | $20.81 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |